Results 201 to 210 of about 27,101 (273)

A Phase 1 Microtracer Study Evaluating the Mass Balance, Excretion, and Pharmacokinetics of Osivelotor in Healthy Participants

open access: yesClinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Osivelotor (GBT021601) is an orally bioavailable, small molecule hemoglobin polymerization inhibitor in clinical development for the treatment of sickle cell disease (SCD). In this Phase 1 study, the disposition of osivelotor was assessed using accelerator mass spectrometry (AMS) after a single oral 200‐mg dose containing a microtracer amount ...
Eric I. Zimmerman   +8 more
wiley   +1 more source

CYP2E1 and CYP2D6 in Anti‐Tuberculosis Drug‐Induced Liver Injury: Mechanisms, Epigenetic Regulation, and Translational Implications

open access: yesClinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Tuberculosis (TB) continues to be a significant global health issue, with anti‐tuberculosis drug‐induced liver injury (ATDILI) representing the most frequent and severe adverse event associated with first‐line therapy. Despite extensive investigation, the mechanistic basis of ATDILI remains incompletely understood.
Pathida Prakongsup   +1 more
wiley   +1 more source

Targeting Brain Cholesterol Homeostasis in Alzheimer's Disease: Mechanisms and Therapeutic Perspectives

open access: yesJournal of Neurochemistry, Volume 170, Issue 6, June 2026.
Brain cholesterol homeostasis is tightly regulated and largely independent of peripheral cholesterol. This review proposes a unifying framework in which aging, sex, and related biological stressors, including hypercholesterolemia, neurodegeneration, inflammation, and oxidative stress, converge to disrupt cholesterol homeostasis in the brain ...
Myuri Ruthirakuhan   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy